Lupus Clinical Trial Awareness in Australia Help Advance Lupus Drug Development Many people diagnosed with lupus still have symptoms despite being treated by their doctor. If you have active discoid and/or subacute cutaneous lupus erythematosus (DLE and/or SCLE), you can volunteer to take part in a research study currently enrolling adult participants. Participants who take…
DetailsResearch Reveals Unique Sub-Groups of Type 2 Lupus (Extract from Lupus Foundation of America) A new study provides insights into the nature of symptoms experienced by people with lupus. While Type 1 and Type 2 lupus models (described below) have previously been identified, the latest research expands upon and refines these definitions, revealing two new…
DetailsStudy Finds mRNA COVID-19 Vaccine and One Booster Dose May Not Fully Protect against Breakthrough Case of Omicron Variant in People with Autoimmune Disease In people with autoimmune rheumatic diseases (ARDs), such as lupus, the mRNA COVID-19 vaccine and booster dose may not provide broad protection from developing a breakthrough infection (an infection with a…
DetailsWorld Lupus Federation Global Survey of People Living with Lupus finds 87% Report at Least One Major Organ Affected by the Disease In a recent international survey, the World Lupus Federation found that 87% of the survey respondents living with lupus reported that the disease has impacted one or more major organs or organ systems. Over…
DetailsSinclair Dermatology are actively seeking male and female Victorian residents aged 18 -80 years with a documented diagnosis of cutaneous lupus erythematosus (CLE) for a minimum of 3 months. Patients are required to have active cutaneous lupus and be a candidate for systemic treatment. Approximately 30-40% of patients with CLE are not responding well to…
DetailsFDA Approves Saphnelo™ as New Treatment for Lupus The U.S. Food and Drug Administration (FDA) has approved Saphnelo™ (anifrolumab-fnia) as a treatment for adults with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. Saphnelo is the third therapy for lupus to receive regulatory approval since 2011. Developed by AstraZeneca, Saphnelo is…
DetailsDo you have SLE?. If yes, the research team at the University of Southern Queensland would highly value your participation in this Doctor of Philosophy research project.
For more information please see the attached flyer:
https://lupusnsw.org.au/wp-content/uploads/2021/06/FREE-Exercise-intervention_SF_2021.pdf
Global Advisory Committee Identifies Solutions for Addressing Top Lupus Barriers The Addressing Lupus Pillars for Health Advancement (ALPHA) project is a unique global consensus initiative that seeks to identify and prioritize the fundamental barriers or knowledge gaps that will allow providers, researchers and scientists to improve diagnosis, treatment and systems of care for people with…
DetailsMore great news for people with lupus! The U.S. Food and Drug Administration (FDA) has approved Lupkynis™ (voclosporin) to treat lupus nephritis (lupus-related kidney disease) in adults when used in combination with a background immunosuppressive therapy regimen. Lupkynis is the second new therapy authorized to treat this potentially life-threatening complication of lupus. Developed by Aurinia…
DetailsGSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA The U.S. Food and Drug Administration (FDA) in late December 2020 approved Benlysta® to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Another milestone, this new…
Details
